LAKE FOREST, Calif.,
Aug. 13, 2020 /PRNewswire/
-- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading
global provider of innovative medical technologies, is pleased to
announce a new FDA clearance to market the Morpheus8 Body handpiece
and Morpheus8 Platform.
Morpheus8 Body is the first intelligent, programmable, full body
fractional technology to deliver clinically proven RF energy up to
a thermal depth of 8mm (7mm pin depth + an additional 1mm thermal
profile), with its 40 gold coated pins. As the first and only
FDA cleared technology to penetrate subdermal tissue with a thermal
profile of 8mm, the new Morpheus8 Body handpiece is designed to
provide physicians with a faster, bigger, and better solution to
deliver customizable full body fractional treatments. Based on the
success of InMode's proprietary technology, the new FDA clearance
extends its line of subdermal adipose remodeling devices
(SARD).
The new Morpheus8 Body will be launched on a new Morpheus8
Platform, a state-of-the-art workstation complete with dual
handpieces and four fractional tips with different microneedle
configurations (Prime 12 pin, Resurfacing 24 pin, Morpheus8 24 pin,
and Body 40 pin). The Morpheus8 Platform provides physicians with a
stand-alone solution for fractional RF, ranging from the Morpheus8
Prime for the treatment of delicate areas with high tissue
curvature, to the Morpheus8 Body for large zones. The Morpheus8
Platform will be revealed to the North American market at InMode's
'Main Event' on August 14 – 16, 2020,
hosted by internationally renowned plastic surgeon, Dr.
Stephen Mulholland.
Shakil Lakhani, InMode President
of North America, commented, "With
InMode being the leader in the RF fractional space, the addition of
these new treatment modalities can provide a customizable, full
body solution for each patient. True innovation in the industry has
become scarce and this is where InMode will continue to thrive. We
are excited about the new treatment capabilities for both our
physicians and their patients."
Dr. Stephen Mulholland added,
"Morpheus8 has become a standard treatment in my clinic. Whether I
use it as a stand-alone treatment for tightening and smoothing of
the skin or combined with one of my other treatments, it is my
go-to treatment for patients looking for significant, but
non-surgical, remodeling improvement."
About InMode
InMode is a leading global provider of innovative medical
technologies. InMode develops, manufactures, and markets
devices harnessing novel radio-frequency ("RF") technology. InMode
strives to enable new emerging surgical procedures as well as
improve existing treatments. InMode has leveraged its
medically-accepted minimally-invasive RF technologies to offer a
comprehensive line of products across several categories for
plastic surgery, gynecology, dermatology, otolaryngology, and
ophthalmology.
For more information about InMode, please visit
www.inmodemd.com.
Press Contact:
Behrman Communications
Amanda Reinstein
areinstein@behrmanpr.com
Investor Contact:
MS-IR LLC
Miri Segal – Scharia
ir@inmodemd.com
917-607-8654
View original
content:http://www.prnewswire.com/news-releases/inmode-introduces-the-morpheus8-platform-and-the-morpheus8-body-fractional-technology-301110212.html
SOURCE InMode Ltd.